Erectile dysfunction is a recognised concern in males living with Friedreich ataxia. When a patient reports difficulty achieving or maintaining an erection in the context of this progressive neurological condition, a specific first-line pharmacological approach is indicated.
This protocol addresses the male patient with Friedreich ataxia who presents with erectile dysfunction. The coexistence of this comorbidity warrants targeted management beyond general ataxia care.
Current evidence supports initiating a specific class of oral therapy directed at the vascular mechanism underlying erectile dysfunction in this population. The complete regimen — including agent selection, initiation criteria, and follow-up — is detailed in the full structured protocol.
We recommend commencing a phosphodiesterase-5 inhibitor in males with Friedreich ataxia who report erectile dysfunction.
DOI: 10.1186/s13023-022-02568-3
View source ↗